Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Blagden

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Nucleic Acids Research|May 1, 2010
The RNA binding protein Larp1 regulates cell division, apoptosis and cell migrationCarla Burrows, Normala Abd Latip, Sarah-Jane Lam, et al.
Elife|April 6, 2017
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAsRoni M Lahr, Bruno D Fonseca, Gabrielle E Ciotti, et al.
Plos One|January 11, 2014
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trialsDavid J Pinato, Chara Stavraka, Michael J Flynn, et al.
Cancer|January 9, 2014
Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trialsChara Stavraka, David J Pinato, Samantha J Turnbull, et al.
BMC Medicine|May 14, 2026
Beyond data and technology: the need for new thinking to enable the era of precision preventionMaria Tsakiroglou, Pradeep Harish, Harry Hemingway, et al.
Oncogene|December 23, 2014
LARP1 post-transcriptionally regulates mTOR and contributes to cancer progressionM Mura, T G Hopkins, T Michael, et al.
British Journal of Cancer|September 13, 2018
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studySarah P Blagden, Ivana Rizzuto, Puvan Suppiah, et al.
British Journal of Cancer|November 26, 2022
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspectiveSarah P Blagden, Ly-Mee Yu, Stephanie Ellis, et al.
British Journal of Cancer|July 22, 2025
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, Tuan Zea Tan, Jae-Weon Kim, et al.
British Journal of Cancer|April 22, 2023
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumorsJason J Luke, Marwan Fakih, Charles Schneider, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Nucleic Acids Research|May 1, 2010
The RNA binding protein Larp1 regulates cell division, apoptosis and cell migrationCarla Burrows, Normala Abd Latip, Sarah-Jane Lam, et al.
Elife|April 6, 2017
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAsRoni M Lahr, Bruno D Fonseca, Gabrielle E Ciotti, et al.
Plos One|January 11, 2014
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trialsDavid J Pinato, Chara Stavraka, Michael J Flynn, et al.
Cancer|January 9, 2014
Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trialsChara Stavraka, David J Pinato, Samantha J Turnbull, et al.
BMC Medicine|May 14, 2026
Beyond data and technology: the need for new thinking to enable the era of precision preventionMaria Tsakiroglou, Pradeep Harish, Harry Hemingway, et al.
Oncogene|December 23, 2014
LARP1 post-transcriptionally regulates mTOR and contributes to cancer progressionM Mura, T G Hopkins, T Michael, et al.
British Journal of Cancer|September 13, 2018
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studySarah P Blagden, Ivana Rizzuto, Puvan Suppiah, et al.
British Journal of Cancer|November 26, 2022
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspectiveSarah P Blagden, Ly-Mee Yu, Stephanie Ellis, et al.
British Journal of Cancer|July 22, 2025
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, Tuan Zea Tan, Jae-Weon Kim, et al.
British Journal of Cancer|April 22, 2023
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumorsJason J Luke, Marwan Fakih, Charles Schneider, et al.
Pageof 6